riliprubart (SAR445088) / Sanofi  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
riliprubart (SAR445088) / Sanofi
NCT04269551: A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease

Completed
1b
12
Europe, US
BIVV020
Bioverativ, a Sanofi company
Autoimmune Haemolytic Anaemia
01/22
01/22
NCT04802057: Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

Active, not recruiting
1
9
Europe
SAR445088
Bioverativ, a Sanofi company
Autoimmune Haemolytic Anaemia
01/26
01/26

Download Options